Treatment decisions in metastatic colorectal cancer - beyond first and second line combination therapies

Overall survival (OS) for patients with metastatic colorectal cancer (mCRC) has markedly improved within the last 2 decades and the most recent generation of randomized clinical trials have yielded median OS durations of 30 months or longer.[1–3] Reasons for this improvement are numerous and multifactorial, although three main points are considered to be the most relevant:

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pMnoWo
via IFTTT